- Home
- SNTI vs ICMB Comparison
SNTI vs ICMB Comparison
Compare SNTI & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ICMB
- Stock Information
- Founded
- SNTI 2016
- ICMB 2012
- Country
- SNTI United States
- ICMB United States
- Employees
- SNTI N/A
- ICMB N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ICMB Finance: Consumer Services
- Sector
- SNTI Health Care
- ICMB Finance
- Exchange
- SNTI Nasdaq
- ICMB Nasdaq
- Market Cap
- SNTI 39.6M
- ICMB 40.6M
- IPO Year
- SNTI N/A
- ICMB N/A
- Fundamental
- Price
- SNTI $1.39
- ICMB $2.89
- Analyst Decision
- SNTI Strong Buy
- ICMB
- Analyst Count
- SNTI 2
- ICMB 0
- Target Price
- SNTI $8.50
- ICMB N/A
- AVG Volume (30 Days)
- SNTI 121.1K
- ICMB 44.4K
- Earning Date
- SNTI 11-13-2025
- ICMB 11-11-2025
- Dividend Yield
- SNTI N/A
- ICMB 16.52%
- EPS Growth
- SNTI N/A
- ICMB N/A
- EPS
- SNTI N/A
- ICMB 0.93
- Revenue
- SNTI N/A
- ICMB $20,422,069.00
- Revenue This Year
- SNTI N/A
- ICMB N/A
- Revenue Next Year
- SNTI $150.00
- ICMB N/A
- P/E Ratio
- SNTI N/A
- ICMB $3.13
- Revenue Growth
- SNTI N/A
- ICMB N/A
- 52 Week Low
- SNTI $1.26
- ICMB $2.46
- 52 Week High
- SNTI $16.94
- ICMB $3.47
- Technical
- Relative Strength Index (RSI)
- SNTI 39.50
- ICMB 49.33
- Support Level
- SNTI $1.33
- ICMB $2.90
- Resistance Level
- SNTI $1.42
- ICMB $3.10
- Average True Range (ATR)
- SNTI 0.07
- ICMB 0.08
- MACD
- SNTI 0.02
- ICMB 0.00
- Stochastic Oscillator
- SNTI 44.83
- ICMB 43.23
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.